Cross-cutting pillar
Weight, metabolism and GLP-1
Weight loss modifies joint load and the systemic inflammatory component. GLP-1 receptor agonists are an active research area; the Observatory describes the available evidence without recommending specific drugs or suggesting tissue regeneration.
This page brings together, in one editorial conversation, the relationship between body weight, body composition, metabolism and osteoarthritis.
When final content is available, we will separate what is demonstrated, what is likely, and what is unknown, with verifiable references.
What the evidence shows
Synthesis of evidence on weight loss, muscle mass and osteoarthritis pending final drafting.
GLP-1 and osteoarthritis
GLP-1 receptor agonists are drugs prescribed by healthcare professionals. The Observatory does not recommend specific drugs: it will present the available data, their limits and their unknowns.
What we don't know
Effect size on symptoms and joint structure beyond effects on weight, across different phenotypes.